A Diabetes Drug Delivery Deal

When deciding whether to approve a drug, the FDA only cares whether it's safe and effective. But once the drug hits the market, a third characteristic -- how the drug is taken -- helps determine whether it obtains blockbuster status.

Most type 2 diabetes patients have started out on oral medications like Bristol-Myers Squibb's (NYSE: BMY  ) Glucophage -- available as generic metformin -- then progressed to injectable insulin. Newer medications like Merck's (NYSE: MRK  ) Januvia sought to put off the inevitable needle pokes by giving patients another oral therapy before heading on to insulin.

Then there's Amylin Pharmaceuticals' (Nasdaq: AMLN  ) Byetta. An analog of the hormone GLP-1, this wonder drug improves glucose levels and helps diabetics shed pounds -- but it has one big problem. Byetta aims to help patients avoid using insulin, but still results in two needle pokes a day, which has put a damper on its sales. Novo Nordisk (NYSE: NVO  ) has tried to best Byetta by developing a competing GLP-1 analog that only needs to be injected once a day.

If one injection a day is better than two, then one injection per week should be seven times better. That's what Amylin and marketing partner Eli Lilly (NYSE: LLY  ) are doing with Byetta. Using Alkermes' (Nasdaq: ALKS  ) microsphere technology, the once-weekly Byetta looked good in trials, although it's still more than a year away from being on the market.

Novo Nordisk isn't waiting idly by to be outdone by once-weekly Byetta, though. The diabetes expert announced yesterday that it's taking drug delivery full circle by attempting to make an oral version of GLP-1-like drugs. It won't be easy; if it were, Amylin, Novo Nordisk, and others would have started there in the first place. But Novo Nordisk thinks it can use Emisphere Technologies' (Nasdaq: EMIS  ) eligen technology to carry GLP-1 drugs across the membranes of the gut and into the bloodstream.

Hold on to your seat, Fools. The GLP-1 drug wars are going to deliver one bumpy ride.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Eli Lilly is a Motley Fool Income Investor recommendation. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 25, 2008, at 7:11 AM, dorfmeister wrote:

    If oral is superior and there is only one oral technology left (offered by ugne.ob). Shouln't that start a bidding war for that one ????? Sanofi, Roche, Merck and who else has something to loose in diabeticss ?

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 671263, ~/Articles/ArticleHandler.aspx, 6/27/2016 1:53:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 17,400.75 -610.32 -3.39%
S&P 500 2,037.41 -75.91 -3.59%
NASD 4,707.98 -202.06 -4.12%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
ALKS $42.28 Down -1.47 -3.36%
Alkermes CAPS Rating: ***
BMY $70.61 Down -2.03 -2.79%
Bristol-Myers Squi… CAPS Rating: ****
EMIS $1.05 Down +0.00 +0.00%
Emisphere Technolo… CAPS Rating: **
LLY $74.33 Up +0.39 +0.53%
Eli Lilly and Co. CAPS Rating: ***
MRK $55.88 Down -1.80 -3.12%
Merck and Co. CAPS Rating: ****
NVO $51.06 Down -2.34 -4.38%
Novo Nordisk CAPS Rating: *****